Efficacy of sodium feredetate versus ferrous sulfate in iron deficiency anemia in preganant women

Revankar, Vijaya Manohar; Garg, Asha Rani; Revankar, Manohar G.

doi:10.18203/2320-1770.ijrcog20171961

Cited by 6 publications

(5 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Regarding the side effects reported by pregnant women taking Ferric Sodium EDTA, only 9.8% mentioned a metallic taste. The same observation was made in the literature regarding a lower incidence of side effects attributable to Ferric Sodium EDTA [14] [49].…”

Section: Discussionsupporting

confidence: 67%

Benefit of Iron Supplementation with Ferric Sodium EDTA (NaFe 3+-EDTA) in the Treatment of Anemia during Pregnancy in Democratic Republic of Congo (FERARI Study)

Mbangama¹,

Muela²,

Mbungu³

et al. 2021

OJOG

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 67%

Benefit of Iron Supplementation with Ferric Sodium EDTA (NaFe 3+-EDTA) in the Treatment of Anemia during Pregnancy in Democratic Republic of Congo (FERARI Study)

Mbangama¹,

Muela²,

Mbungu³

et al. 2021

OJOG

View full text Add to dashboard Cite

“…21 In another recent study between two types of oral iron supplementation, none of the patients in sodium feredetate group experienced metallic taste while 20% in ferrous sulphate group reported metallic taste as a significant side effect. 22 Micro-encapsulated iron pyrophosphate tablets with the brand name FERFER manufactured by PharmEvo. Pvt.…”

Section: Resultsmentioning

confidence: 99%

Palatability of micro-encapsulated iron pyrophosphate (Ferfer®)

Siddiqui¹,

Ashraf

Imran³

2018

Int J Clin Trials

View full text Add to dashboard Cite

Background: Iron deficiency is the leading cause of anemia globally and affects 20% of world adult population. The general practice for replacement of iron reserves is oral supplementation. However, the success of this strategy solely depends on drug adherence and compliance. Where many other factors contribute to compliance, the role of taste of the medicine can also not be neglected. The aim of this study is to evaluate the palatability of micro-encapsulated iron pyrophosphate (Ferfer) and compare its taste with previously taken other oral forms of iron supplements.Methods: The study was conducted with 231 female participants of age more than 18 years. Participants had taken one sachet of micro-encapsulated iron pyrophosphate (Ferfer) for the purpose of taste. Questionnaire based on their previous experience of iron supplements and palatability of Ferfer was asked by participants based on 0-10 mm visual analogue scale and 5 point Likert scale evaluating responses at 0 minute, 5 minute, and at 10 minute. Data was analyzed by using SPSS version 23.Results: The women previously taking some others oral form of iron supplementation scored their supplements, a mean taste score is 2.92±2.44 on the VAS. However, micro-encapsulated iron pyrophosphate (Ferfer) received a mean score of 7.66±1.32 immediately after taking it and a score of 7.96±1.37 after 5 minutes on the 0-10 mm VAS. 81.4% patients will recommend their doctors to prescribe FERFER to them in future.Conclusions: Enhanced palatability of micro-encapsulated iron pyrophosphate sachets have resulted in increased compliance to the supplementation regimen among the participants.

show abstract

“…As well as a significantly greater increase in Hb, there were significantly fewer side effects seen with sodium feredetate than ferrous sulphate. 32 This study also highlighted the improved bioavailability of sodium feredetate as this cohort was given one 231 mg tablet once per day for 2 months (equivalent to 33 mg of elemental iron) compared with the ferrous sulphate cohort who were given 200 mg tablets two times per day for 2 months (equivalent to 60 mg of elemental iron).…”

Section: Introductionmentioning

confidence: 83%

Iron deficiency anaemia: pathophysiology, assessment, practical management

Kumar

Sharma

Marley

et al. 2022

BMJ Open Gastroenterol

131

View full text Add to dashboard Cite

The WHO has recognised iron deficiency anaemia (IDA) as the most common nutritional deficiency in the world, with 30% of the population being affected with this condition. Although the most common causes of IDA are gastrointestinal bleeding and menstruation in women, decreased dietary iron and decreased iron absorption are also culpable causes. Patients with IDA should be treated with the aim of replenishing iron stores and returning the haemoglobin to a normal level. This has shown to improve quality of life, morbidity, prognosis in chronic disease and outcomes in pregnancy. Iron deficiency occurs in many chronic inflammatory conditions, including congestive cardiac failure, chronic kidney disease and inflammatory bowel disease. This article will provide an updated overview on diagnosis and management of IDA in patients with chronic conditions, preoperative and in pregnancy. We will discuss the benefits and limitations of oral versus intravenous iron replacement in each cohort, with an overview on cost analysis between the different iron formulations currently on the market.

show abstract

Efficacy of sodium feredetate versus ferrous sulfate in iron deficiency anemia in preganant women

Cited by 6 publications

References 3 publications

Benefit of Iron Supplementation with Ferric Sodium EDTA (NaFe <sup>3+</sup>-EDTA) in the Treatment of Anemia during Pregnancy in Democratic Republic of Congo (FERARI Study)

Benefit of Iron Supplementation with Ferric Sodium EDTA (NaFe <sup>3+</sup>-EDTA) in the Treatment of Anemia during Pregnancy in Democratic Republic of Congo (FERARI Study)

Palatability of micro-encapsulated iron pyrophosphate (Ferfer®)

Iron deficiency anaemia: pathophysiology, assessment, practical management

Contact Info

Product

Resources

About

Efficacy of sodium feredetate versus ferrous sulfate in iron deficiency anemia in preganant women

Cited by 6 publications

References 3 publications

Benefit of Iron Supplementation with Ferric Sodium EDTA (NaFe &lt;sup&gt;3+&lt;/sup&gt;-EDTA) in the Treatment of Anemia during Pregnancy in Democratic Republic of Congo (FERARI Study)

Benefit of Iron Supplementation with Ferric Sodium EDTA (NaFe &lt;sup&gt;3+&lt;/sup&gt;-EDTA) in the Treatment of Anemia during Pregnancy in Democratic Republic of Congo (FERARI Study)

Palatability of micro-encapsulated iron pyrophosphate (Ferfer®)

Iron deficiency anaemia: pathophysiology, assessment, practical management

Contact Info

Product

Resources

About

Benefit of Iron Supplementation with Ferric Sodium EDTA (NaFe <sup>3+</sup>-EDTA) in the Treatment of Anemia during Pregnancy in Democratic Republic of Congo (FERARI Study)

Benefit of Iron Supplementation with Ferric Sodium EDTA (NaFe <sup>3+</sup>-EDTA) in the Treatment of Anemia during Pregnancy in Democratic Republic of Congo (FERARI Study)